Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients

Abstract

J.G. Mulhern reports serving as medical director at Fresenius Kidney Care dialysis unit and receiving research funding from Boehringer Ingelheim, Calliditas, and Reata Pharmaceuticals.C. Mullon reports employment with Fresenius Medical Care North America, having stock in Fresenius Medical Care as an employee of the company, and receiving funding from Fresenius Medical Care for research activities.J. Willetts reports employment with Fresenius Medical Care.

Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients

“…Among maintenance dialysis patients, mRNA vaccines against SARS-CoV-2 elicited appropriate seroresponse in the vast majority, consistent with prior reports of mRNA vaccines worldwide. 4–7 In contrast, seroresponse to the Ad26.COV2.S/Janssen vaccine was low, consistent with an earlier small study, 8 and suggesting that mRNA-based SARS-CoV-2 vaccines should be recommended for maintenance dialysis patients, particularly given their high morbidity and mortality from COVID-19. 12…”

“…Studies to date suggest a high seroresponse rate (greater than 80%) to mRNA vaccines in maintenance dialysis patients, albeit less than that in the general population. 4–7 A report in 76 dialysis patients that Ad26.COV2S elicits lower seroresponse warrants further study; 8 moreover, small sample sizes have so far limited evaluation of predictors of non-response. Accordingly, we retrospectively analyzed seroresponse to SARS-CoV-2 vaccines in maintenance dialysis patients, updating an earlier report.…”

Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients

“…Among maintenance dialysis patients, mRNA vaccines against SARS-CoV-2 elicited seroresponse in the vast majority, consistent with prior reports. [1][2][3][4][5][6] In contrast, seroresponse to the Ad26.COV2.S/Janssen vaccine was low, consistent with an earlier small study, 7 suggesting that maintenance dialysis patients should receive mRNA-based SARS-CoV-2 vaccines, particularly given their high morbidity and mortality from COVID-19. 9 The low seroresponse rate to the Ad26.COV2.S/Janssen vaccine is concerning because post-vaccination SAb-IgG antibody titers correlate with protection from COVID-19, possibly via direct neutralization of the spike protein.…”

“…[1][2][3][4][5][6] Data regarding adenoviral vector vaccines and predictors of vaccine non-response are limited by small sample sizes. 7 Accordingly, we retrospectively analyzed seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients, updating an earlier report. 8 Dialysis Clinic, Inc. (DCI) is a national not-for-profit provider caring for more than 15,000 patients at 260 outpatient dialysis clinics across 29 states.…”

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

“…A similar pattern of improved responses in infection-experienced patients, in anti-S titres rather than neutralising antibody, has been reported for the single-dose adenoviral-vectored vaccine Ad26.CoV.2. 13 are likely to offer the broadest VOC nAb coverage. The UK's JCVI has announced third doses, in principle, for many vulnerable groups.…”